FDA grants fast track designation to Complement Therapeutics’ CTx001 for geographic atrophy

The FDA has granted fast track designation to Complement Therapeutics’ CTx001, the company’s lead gene therapy candidate for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The investigational new drug (IND) application for CTx001 submitted by Complement Therapeutics was previously approved by the agency in October 2025, allowing the company to initiate the Opti-GAIN phase 1/2 clinical trial.

Opti-GAIN is an international first-in-human, open-label study designed to evaluate the safety, tolerability, and preliminary efficacy of CTx001. First dosing is expected to begin in the US during Q1 of 2026.

Fast track designation from the FDA is intended to facilitate the development and expedite review of drugs that treat serious conditions and have the potential to address unmet medical needs. It is designed to support more frequent interactions with the FDA and bring important new therapies to patients sooner.¹

Rafiq Hasan, MD, CEO of Complement Therapeutics, commented on the FDA’s decision in a press release from the company, saying, "FDA fast track designation for CTx001 is an important regulatory milestone recognizing the seriousness of geographic atrophy, the unmet medical need faced by patients, [and] the innovative potential for CTx001 to meaningfully address this need. Together with the recent IND clearance, this designation supports our efforts to efficiently advance CTx001 into clinical development as we work to address a leading cause of irreversible vision loss."

The company defines CTx001 as an adeno-associated virus (AAV)–based gene therapy that is designed to deliver a truncated version of CR1. According to the company, this enables long-term modulation of the “classical and alternative pathways of the complement cascade.” The company describes the complement cascade as “part of the immune system that enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen’s cell membrane.”^1,2

Furthermore, the company notes that dysregulation of the complement system is implicated in the development of several diseases, including AMD, kidney disease, and various hematological conditions. Complement Therapeutics also noted that research conducted by the company founders identified the pivotal role of factor H–related proteins in the development of AMD, providing the foundation for the therapeutic strategy being pursued by the company with CTx001.^1,2

References

1. Complement Therapeutics announces FDA fast track designation for CTx001 for the treatment of geographic atrophy secondary to AMD. News release. Complement Therapeutics GmbH. January 8, 2026. Accessed January 12, 2026. https://www.prnewswire.com/news-releases/complement-therapeutics-announces-fda-fast-track-designation-for-ctx001-for-the-treatment-of-geographic-atrophy-secondary-to-amd-302655523.html

2. Harp MD. FDA clears IND for Complement Therapeutics’ CTx001 gene therapy in geographic atrophy. Ophthalmology Times. October 8, 2025. Accessed January 12, 2026. https://www.ophthalmologytimes.com/view/fda-clears-ind-for-complement-therapeutics-ctx001-gene-therapy-in-geographic-atrophy